Related Experiment Video
Updated: May 15, 2026
06:54
Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells
Published on: October 27, 2020
Targeting IGF-1 signaling pathways in gynecologic malignancies
1Department of Human Molecular Genetics and Biochemistry, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.
Expert Opinion on Therapeutic Targets
|January 9, 2013
Summary
The insulin-like growth factor-1 receptor (IGF-1R) pathway is crucial in gynecologic cancers. Targeting IGF-1R shows significant promise in preclinical and clinical studies for treating ovarian and endometrial cancers.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Therapeutics
Background:
- Insulin-like growth factors (IGF) signaling pathways are implicated in epithelial neoplasms.
- IGF-1 receptor (IGF-1R) is expressed in transformed cells, promoting survival and transformation.
- IGF-1R expression and activation are hallmarks of tumor initiation and progression.
Purpose of the Study:
- To review research on the IGF axis role in gynecologic cancers.
- To discuss preclinical and clinical studies in cervical, uterine, and ovarian cancers.
- To examine IGF pathway targeting therapies in gynecologic malignancies.
Main Methods:
- Literature review of preclinical and clinical studies.
- Analysis of IGF axis significance in tumor expression and circulating levels.
- Discussion of IGF-1R targeting therapies.
Main Results:
- IGF-1R pathway plays a significant role in gynecologic cancers.
- IGF-1R targeted therapies show impact in ovarian and endometrial cancers.
- Ongoing trials are evaluating the efficacy of IGF-1R targeting.
Conclusions:
- Accumulating data confirm the importance of the IGF-1R pathway in gynecologic cancers.
- In vivo and in vitro studies demonstrate the impact of IGF-1R targeted therapies.
- Further understanding of IGF system regulation will enhance treatment modalities.
Related Concept Videos
02:38Mitogens and the Cell Cycle
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
03:03mTOR Signaling and Cancer Progression
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
01:19Interactions Between Signaling Pathways
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...